

April 29, 2026

To

BSE Limited

The Corporate Relationship Dept.
P.J. Towers, Dalal Street
Mumbai - 400 001

Scrip Code: 500214

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block- G,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: IONEXCHANG

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") we wish to inform that the Company has executed a Technology Transfer Agreement ("Agreement") with MANN + HUMMEL.

Under the Agreement, MANN + HUMMEL has, inter alia, agreed to transfer technology for the manufacture of PVDF Ultrafiltration (UF) membranes and Integrated Membrane Bioreactor (MBR) systems.

The Agreement has been entered into in the ordinary course of business and is expected to support the Company's long-term strategic and technological objectives.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in 'Annexure – A'.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For Ion Exchange (India) Limited

Nikisha Solanki

Company Secretary & Compliance Officer
ACS 50894

Encl: As stated above

Details as required under SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sl. No.	Particulars	Disclosure
i.	Name of the entity(ies) with whom agreement is signed;	MANN + HUMMEL
ii.	Area of agreement	Strategic technology transfer and manufacturing collaboration for the production of advanced PVDF Ultrafiltration (UF) membranes with integrated UltraSKID systems, and subsequently, a technology transfer of Membrane Bioreactor (MBR) solutions for deployment in India
iii.	Domestic/international	Both Domestic and International
iv.	Share exchange ratio	Not Applicable
v.	Scope of business operation of agreement	Ion Exchange will manufacture, undertake system integration, and commercialize PVDF hollow fiber ultrafiltration membranes along with integrated UltraSKID systems based on MANN+HUMMEL's advanced technology. Production will take place at Ion Exchange's expanded, state-of-the-art HYDRAMEM® membrane manufacturing facility in Goa
vi.	Details of consideration paid / received in agreement	Technology transfer fee of 7.5% on revenue generated from manufactured products
vii.	Significant terms and conditions of agreement	Transfer of technical know-how, including manufacturing processes, formulations, and best practices
viii.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not a related party transaction
ix.	Size of the entity(ies)	Not Applicable

x.	Rationale and benefit expected	The collaboration strengthens Ion Exchange's HYDRAMEM® solutions to offer an integrated portfolio of membrane-based technologies, including Ultrafiltration (UF), Reverse Osmosis (RO) and Membrane Bioreactor (MBR) systems. It will enable the Company to deliver globally benchmarked membrane technology manufactured locally, reduce import dependence and ensure improved supply reliability and faster delivery timelines for customers.
----	--------------------------------	---